id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-310217-p9nqcz5d	Nikolina, Basic-Jukic	Can hyperimmune anti-CMV globuline substitute for convalescent plasma for treatment of COVID-19?	2020-05-31		.txt	text/plain	648	43	40	Currently available expert opinions suggest reduction of immunosuppression therapy for renal transplant recipients with symptomatic COVID-19 infection with either antiviral drugs, hydroxychloroquine and/or azithromycin. Currently available expert opinions suggest reduction of immunosuppression therapy for renal transplant recipients with symptomatic COVID-19 Inspired by our experience in treatment of CMV pneumonia and literature data on the potential benefit of convalescent plasma for treatment of different viral diseases we suggest use of the hyperimmune anti-CMV gamma globulins in addition to other available therapies. Inspired by our experience in treatment of CMV pneumonia and literature data on the potential benefit of convalescent plasma for treatment of different viral diseases we suggest use of the hyperimmune anti-CMV gamma globulins in addition to other available therapies. In conclusion, we suggest the use of hyperimmune anti-CMV immunoglobulins for treatment of COVID-19 especially when occur as coinfection with CMV instead of the convalescent plasma which may be unavailable for majority of patient.	./cache/cord-310217-p9nqcz5d.txt	./txt/cord-310217-p9nqcz5d.txt